Catabasis Pharmaceuticals, Inc. is on the Cruelty Free Investing use of animals list because they use animals for drug testing and clinical trials.
The company announced in the following Press release, “Catabasis is developing CAT-4001 as a potential treatment for neurodegenerative diseases such as Friedreich’s ataxia (FA) and amyotrophic lateral sclerosis (ALS). CAT-4001 is a small molecule that activates Nrf2 and inhibits NF-kB, two pathways that have been implicated in FA and ALS. Catabasis has shown that CAT-4001 modulates the Nrf2 and NF-kB pathways in both cellular assays and animal models. ” Read the full article.
Catabasis Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery, development, and commercialization of therapeutics for the treatment of cardiovascular, metabolic and inflammatory diseases. The company was founded by Jill C. Milne, Michael Jirousek and Steven Shoelson on June 26, 2008 and is headquartered in Cambridge, MA. [Source: MarketWatch]
Company Website: http://www.catabasis.com